The Menopause Digest 07/14 - 07/20

Welcome to The Menopause Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

The biggest shift in this week’s crop of episodes: clinicians are moving past “normal” lab values toward “optimal” targets and tissue-level truth. On The DUTCH Podcast, the hosts make the case that serum androgens can look pristine while urinary metabolites like 5α-androstanediol expose DHT quietly miniaturizing hair follicles—a reminder that the follicle doesn’t read the same labs your doctor does. Sequencing matters too: cortisol first, then androgens, then micronutrients, because chasing hair loss with biotin while ignoring HPA-axis strain is like mopping a floor with the faucet still running.

That same precision ethos shows up in HRT dosing philosophy. Menopause Matters, Let’s Talk pushes back on the mythology of “body-identical” magic bullets, arguing instead for simple, individualized regimens—transdermal estradiol plus a 52 mg levonorgestrel IUS for endometrial protection—paired with disciplined 3-month follow-up. Meanwhile, Dr. Heather Hirsch’s Health By Heather Hirsch episode delivers a sharper verdict: cycling HRT after menopause is largely a physiological dead end, provoking withdrawal bleeding and even vasospasm, whereas steady-state dosing respects vascular biology. Together, these three episodes tell the same story from different angles—menopause care is getting less “one-size-fits-all” and more “measure twice, dose once.”

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

If there’s a commercial and clinical epicenter this week, it’s the collision of menopause and GLP-1 therapy. Hit Play Not Pause, featuring Dr. Carla DiGirolamo, reframes PCOS as “PMOS”—polyendocrine metabolic ovarian syndrome—arguing that insulin resistance, not ovarian cysts, is the disease’s real engine, and that it compounds with menopausal estrogen decline. Her intriguing hook: MHT may actually sensitize GLP-1 signaling, hinting at a synergistic hormone-plus-peptide future for midlife metabolic care.

Not Your Mother’s Menopause takes a different lane, spotlighting a delayed-release bitter hop extract (Amarasate/Calocurb) that nudges the body’s own satiety hormones—GLP-1, CCK, PYY—into action, positioning it as a bridge therapy for patients tapering off injectables. And on the access side, The Plus SideZ unpacks the new Medicare GLP-1 “Bridge” demonstration (July 2026–Dec 2027), a $50/month copay pilot outside standard Part D rules that could be a watershed for obesity-care coverage—if clinics master the claim-then-PA workflow CMS demands. The throughline: GLP-1s are no longer just a weight-loss drug category; they’re becoming a menopause-management infrastructure question.

Several episodes push clinicians to look past the hormone panel entirely. The Girlfriend Doctor, with guest Dr. Catherine Clinton, frames 3 a.m. wake-ups as a quantum biology problem—morning sunlight and evening darkness recalibrating the cortisol-melatonin axis before any supplement gets involved. Menopause Mastery delivers perhaps the week’s most urgent clinical flag: chronic psychological abuse can accelerate menopause onset and masquerade as garden-variety perimenopausal anxiety, making IPV screening a non-negotiable part of the visit. On the supply side, Sky Women’s Health documents a genuine crisis—an estradiol patch shortage tied partly to surging demand after the FDA’s black-box warning removal—pointing clinicians toward direct-to-pharmacy cash models like HRT Club to keep patients from going without therapy. And rounding out the practical toolkit, OvaryActive draws a hard line between unregulated peptide injections (avoid) and oral creatine (a reasonable, evidence-backed adjunct to resistance training), while The Skin Real and Dr. Barbie Taylor’s ovarian cancer episode reinforce that microneedling and modifiable lifestyle habits remain unglamorous but effective levers for skin and cancer-risk outcomes, respectively.

URL: Listen Here

This episode outlines a comprehensive, root-cause approach to hair loss that extends beyond basic labs to include tissue-level androgen assessment, HPA-axis evaluation, thyroid antibodies, iron optimization, micronutrient status, and gut health. It emphasizes sequencing care (cortisol first), setting optimal—not just normal—targets (e.g., ferritin and TSH), and using evidence-based nutrition and botanicals while being cautious about low-yield supplements and lifelong therapies.

• Hair loss is often multifactorial; a narrow workup (e.g., TSH only, basic CBC) frequently misses drivers such as tissue-level androgen excess, cortisol dysregulation, micronutrient deficits, gut inflammation/dysbiosis, and toxins.

• Androgens—especially DHT via 5-alpha-reductase—miniaturize follicles; serum totals can look ‘normal’ while tissue activity is high. Urinary androgen metabolites (e.g., 5α-androstanediol) better reflect follicular DHT activity than serum alone.

• Stress and cortisol can precipitate telogen effluvium with a 2–3 month lag. Postpartum estrogen drop, chronic HPA-axis strain, rapid weight loss/GLP-1 use, and poor protein/micronutrient intake commonly trigger or worsen shedding.

• Thyroid and iron parameters need optimal—not merely normal—targets: full thyroid panel with antibodies; aim TSH <2.5 and ferritin ≥50–80 ng/mL (and interpret ferritin alongside hs-CRP because inflammation can falsely elevate ferritin).

• Management works best in sequence: stabilize cortisol and blood sugar, address androgen excess and sex-hormone balance, replete micronutrients (e.g., vitamin D, B12, zinc, selenium), optimize protein intake (~100 g/day for many adults), and address gut dysbiosis/inflammation; be cautious with quick fixes (biotin has limited benefit; minoxidil works but requires lifelong use).

Tissue-level androgen activity—particularly DHT generated by 5‑alpha‑reductase—is a major, frequently missed driver of female hair loss; serum hormones can appear normal while urinary metabolites (e.g., 5α‑androstanediol) reveal clinically relevant androgen excess at the follicle.

In any patient with diffuse hair shedding, order an expanded workup: TSH, free T4, free T3, reverse T3, TPO/Tg antibodies; iron, TIBC, ferritin plus hs-CRP; vitamin D, B12, zinc/selenium; and consider urinary hormone testing for androgen metabolites (including 5α-androstanediol) and a diurnal cortisol profile—then treat iron deficiency to ferritin ≥50–80 ng/mL, support HPA-axis health, and raise dietary protein toward ~100 g/day while repleting demonstrated micronutrient gaps.

URL: Listen Here

This episode clarifies HRT fundamentals, indications, delivery options, and practical selection while countering myths about so-called body-identical regimens, emphasizing simple, individualized approaches with attention to adherence and bleeding. The hosts highlight not starting HRT before symptoms, the utility of the levonorgestrel IUS for endometrial protection, and the importance of structured follow-up and lifestyle measures, alongside using trustworthy information sources. Limitations: no specific trials were named; points largely reflect expert consensus and current practice.

• Systemic HRT consists of estrogen (transdermal gel, patch, spray, or oral estradiol) plus a progestogen for anyone with a uterus to protect the endometrium; route and regimen should be individualized to symptoms, preferences, and comorbidities.

• Main indications are symptom control; premature or early menopause to protect bone and cardiovascular health; and osteoporosis risk (particularly under age 60) when symptomatic.

• There is no test that predicts the ideal HRT regimen; start simple, counsel on strict adherence and consistent timing, expect trial and error titration, and anticipate that unscheduled bleeding is common in the first 3 months.

• Micronized progesterone may be well tolerated but can control bleeding less reliably for some; a 52 mg levonorgestrel intrauterine system (for example, Mirena) often optimizes endometrial protection, reduces bleeding, and provides contraception.

• Do not start HRT preemptively before symptoms; arrange a 3-month review then annual reviews, and use a risk-benefit approach for long-term continuation, noting that initiation in very late life (for example, around 75 years) is generally a specialist, off-label decision.

Effective and safe HRT use hinges on individualized, simple regimens with reliable endometrial protection and proactive bleeding management; avoid preemptive initiation before symptoms and ensure structured follow-up to adjust therapy.

When starting transdermal estradiol in a perimenopausal patient with a uterus, offer a 52 mg levonorgestrel IUS for progestogen coverage, provide clear adherence counseling (including consistent application timing), advise that unscheduled bleeding may occur in the first 3 months, and schedule a 3-month review to optimize dose and regimen.

URL: Listen Here

This episode explores biologic drivers of menopausal weight gain and the role of the gut–brain axis, highlighting evidence that a delayed-release bitter hop extract can boost endogenous satiety hormones (GLP-1, CCK, PYY) and reduce hunger, cravings, and caloric intake. It outlines practical integration with GLP-1 therapies (alternative, combination for lower dosing, and taper/maintenance) and emphasizes preserving lean mass with adequate protein and resistance training.

• Midlife weight gain is common: women average ~22 lb during perimenopause, and would need ~200 fewer kcal/day for a decade to offset it; hormones, stress, sleep, and insulin resistance all shift eating behavior.

• Female-specific clinical testing of a delayed-release bitter hop extract (Amarasate; marketed as Calocurb) during a 24-hour fast reported no rise in hunger at 24h vs 16h (”100% decrease in increased appetite”), a 120% reduction in cravings, and ~14.5% lower caloric intake at the test meal.

• Bitter taste receptor activation in the upper small intestine can stimulate endogenous satiety hormones (CCK, GLP-1, PYY); an early human study in men found ~600% increases in these hormones and ~18% (~220 kcal) lower intake after dosing the hop extract.

• Clinical use-cases discussed: as an alternative to GLP-1 injectables (for cost/tolerability/injection aversion), in combination to enable lower GLP-1 doses, and to support taper/maintenance when discontinuing injectables by re-stimulating endogenous gut–brain satiety signaling.

• To preserve lean mass and reduce sarcopenia risk during weight loss, prioritize protein intake (~120 g/day for many peri/postmenopausal women) and resistance training; the hop-extract effect lasts ~4–6 hours when taken as two delayed-release capsules ~1 hour before lunch and dinner after a brief dose ramp.

Appetite and weight regulation in menopause are driven largely by gut–brain hormonal signaling (GLP-1/CCK/PYY), not “willpower”; activating endogenous satiety pathways via targeted bitter-taste receptor stimulation can meaningfully reduce hunger, cravings, and intake, and can complement or help taper off GLP-1 drugs.

If planning to discontinue a GLP-1 injectable, create a structured taper that starts a physiologic appetite modulator (e.g., delayed-release bitter hop extract) 1–2 weeks before the final dose to re-engage endogenous satiety signaling and blunt rebound hunger.

URL: Listen Here

This episode explains the upcoming Medicare GLP-1 Bridge program—who qualifies, how it differs from Part D, required documentation, and a practical submission sequence likely involving an initial pharmacy claim denial before PA. It also outlines coverage alternatives and cash-pay options, emphasizing how the pilot could catalyze broader GLP-1 access across payers.

• CMS will run a separate, national Medicare “Bridge” demonstration (July 1, 2026–Dec 31, 2027) to provide select GLP-1s for long-term weight management to eligible Part D enrollees at a fixed $50/month copay; this program is outside the standard Part D benefit and does not count toward deductibles or out-of-pocket maximums.

• Eligibility focuses on BMI thresholds (generally ≥27 with qualifying comorbidities; ≥30 without; and higher BMI tiers) and requires Part D enrollment; patients already eligible for GLP-1 coverage via other Part D–covered, non-obesity indications (e.g., type 2 diabetes, established CVD, moderate OSA) are steered to those pathways and not the Bridge program.

• Thorough documentation is critical: capture starting (pre-therapy) and current weight/BMI, qualifying comorbidities, pertinent labs, medication history, and prior weight-loss interventions to minimize denials and delays.

• Process nuance: clinics may need to send an initial prescription to the dispensing pharmacy to generate a claim and initial rejection before submitting the prior authorization under the Bridge program; correct pharmacy processing and clear clinic workflows will be essential.

• For those not eligible, alternatives include coverage through other FDA-approved indications (e.g., T2D, CVD risk reduction, OSA), cash-pay options for branded GLP-1s, older/generic anti-obesity medications (e.g., liraglutide), and telehealth-access pathways.

The Medicare Bridge demonstration could be a watershed in U.S. obesity-care access; preparing robust documentation and adopting the specific claim-then-PA workflow can improve approval success and position clinics for broader payer coverage shifts if CMS expands long-term GLP-1 coverage after the pilot.

Implement a standardized clinic checklist and workflow for Bridge submissions: confirm Part D enrollment and BMI/comorbidity criteria; document starting (pre-therapy) weight/BMI, current weight, comorbidities, labs, and prior therapies; e-prescribe to the dispensing pharmacy to generate the initial claim/rejection; then submit the prior authorization, and counsel patients that the $50 copay is fixed and does not apply to Part D deductibles/OOP.

URL: Listen Here

This episode reframes PCOS as PMOS, underscoring its lifelong metabolic implications that persist—and often intensify—through the menopause transition. It reviews diagnosis, the central role of insulin resistance, evolving treatments (metformin, inositol, GLP‑1 RAs), and how MHT may enhance GLP‑1 signaling, offering a potentially synergistic approach to midlife metabolic health in active women.

• PCOS has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to emphasize that it is a systemic endocrine–metabolic disorder; ovarian findings are only one component.

• Diagnosis (Rotterdam criteria) requires 2 of 3: irregular/absent menses, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology; phenotypes range from “lean PMOS” to BMI ≥30, and misdiagnosis (both over- and under-) is common.

• Insulin resistance is central and multifactorial (intrinsic insulin receptor defect, androgen excess); during menopause, estrogen decline, relative hyperandrogenism, visceral fat gain, and GLP‑1 pathway desensitization compound metabolic risk.

• Management in reproductive age often includes metformin and evidence‑based use of inositol; GLP‑1 receptor agonists can outperform metformin for weight and insulin sensitivity in higher‑BMI phenotypes but are not pregnancy‑safe and are unstudied in lean PMOS.

• Menopausal hormone therapy (MHT) may improve insulin sensitivity via GLP‑1 pathway effects and may act synergistically with GLP‑1 RAs; be cautious with adding testosterone in PMOS due to potential worsening of hyperandrogenism and insulin resistance.

In perimenopause and menopause, PMOS primarily manifests as elevated cardiometabolic risk due to compounded insulin resistance from estrogen decline and relative hyperandrogenism; clinicians should prioritize metabolic screening and targeted therapies (e.g., MHT, and GLP‑1 RAs when indicated) over reproductive features that recede with age.

For midlife women with known or suspected PMOS, proactively screen for metabolic syndrome: order fasting glucose, HbA1c, fasting insulin, a lipid panel, and measure blood pressure; use results to guide referral (endocrinology/menopause specialist), nutrition counseling, and consideration of metformin or GLP‑1 therapy per FDA criteria and reproductive plans.

URL: Listen Here

This episode explores how ‘invisible’ abuse—coercive control, gaslighting, and financial domination—can overlap with and worsen perimenopausal symptoms, potentially contributing to earlier menopause through chronic stress. It emphasizes recognition of red flags, careful clinical screening to distinguish abuse-related distress from menopausal changes, and stepwise strategies and community resources that help women move from victim to survivor.

• Chronic, prolonged psychological abuse (coercive control, gaslighting, isolation, and financial abuse) can overlap with and intensify perimenopausal symptoms and may contribute to earlier menopause via stress-related neuroendocrine disruption.

• Abuse is often ‘invisible’: key red flags include misalignment between a partner’s words and actions, delayed punitive outbursts tied to earlier grievances, social isolation, and progressive restriction of financial access.

• Misattributing abuse-related anxiety, insomnia, and brain fog solely to menopause can delay recognition of intimate partner violence; journaling and pattern-tracking can help validate a patient’s reality.

• Recovery hinges on acceptance, education, boundary-setting, and small, methodical steps; forgiveness is framed as self-liberation rather than excusing harm.

• Structured supports (Victim to Warrior Method, workbooks, quizzes, community groups, and a private mobile app) can aid safety, clarity, and healing; loved ones should keep doors open without directly confronting the abuser.

In women presenting with severe perimenopausal symptoms—especially anxiety, insomnia, and vasomotor instability—clinicians should screen for intimate partner violence and coercive control (including financial abuse), as chronic stress from abuse may precipitate earlier menopause and exacerbate symptoms; avoid anchoring on menopause alone.

Add brief, trauma-informed IPV/coercive-control screening to perimenopause/menopause visits (e.g., safety at home, isolation, control over finances, alignment of partner’s words vs actions), document findings, validate the patient, discreetly offer resources/referrals (social work, counseling), and support safe journaling/pattern-tracking when appropriate.

URL: Listen Here

This episode reframes midlife sleep disruption through a quantum biology lens, emphasizing how the spectrum, timing, and intensity of light program hormones, mitochondria, metabolism, and the nervous system. Practical circadian strategies—morning outdoor light, daytime light breaks, evening darkness/amber light, infrared support, and a calming bedtime routine—are presented as foundational before supplements or medications. Some mechanisms discussed (e.g., broader ‘quantum biology’ applications) are emerging and not uniformly established across clinical guidelines.

• Morning natural light within 30 minutes of waking is a powerful circadian cue that gently elevates cortisol, synchronizes cellular clocks, and supports sex hormone production, metabolism, mood, and immune balance—whereas starting the day with narrow-spectrum blue/LED light (phones/screens) can spike cortisol and dysregulate this rhythm.

• Evening light hygiene is essential: after sunset, use low, warm/amber, floor-level lighting (e.g., salt lamps/incandescent), limit screens/blue light, and sleep in a cool, dark room to allow melatonin to rise; even low-intensity light at night can blunt melatonin and degrade sleep quality.

• In high latitudes or for shift workers, still anchor light exposure to wake time, take daylight “light breaks,” and consider red/near-infrared exposure (sunlight, sauna, photobiomodulation) or fuller-spectrum indoor lighting to support mitochondrial function and circadian alignment when daylight is scarce.

• Skin is a photobiologic and endocrine organ; sensible sun on skin and through the eyes supports vitamin D and other light-mediated signaling that influence hormones, inflammation, and metabolism—while practicing safe sun habits and avoiding over-soaping immediately after sun if optimizing cutaneous vitamin D production.

• A simple, consistent rhythm—morning outdoor light, daytime light breaks, calming evening routine (gratitude/heart-coherence, avoiding late meals/alcohol/screens), and adjuncts like tart cherry and magnesium—can markedly reduce 2–4 a.m. awakenings and improve restorative sleep in peri- and postmenopausal women.

Circadian realignment—prioritizing natural morning light exposure and strict evening light management to normalize the cortisol–melatonin axis—is a high-impact, low-risk first-line strategy for perimenopausal insomnia and 3 a.m. awakenings that can also stabilize mood, reduce inflammation, and improve metabolic and mitochondrial function.

Prescribe a 7-day circadian reset: within 30 minutes of waking, spend 5–10 minutes outdoors (no sunglasses; avoid phone use), take 2–3 short daylight “light breaks,” and after sunset use only low, warm lighting and block blue light; sleep in a cool (~18°C/65°F), dark room (blackout curtains; no status LEDs). Optional adjuncts 1–2 hours pre-bed: tart cherry (juice 240–480 mL or extract providing ~100–1200 µg melatonin) and magnesium 200–400 mg (glycinate or L‑threonate), avoiding heavy meals/alcohol and screens.

URL: Listen Here

This episode critically reviews two highly marketed interventions: unregulated peptide injections and oral creatine. The hosts strongly discourage peptide use outside research settings due to minimal human data and safety concerns, while supporting creatine as a generally safe adjunct to resistance training with modest muscle benefits but inconclusive evidence for bone, cognitive, or mood outcomes. Practical guidance includes selecting verified supplement products and avoiding any injectable versions sold outside medical care.

• Peptide injections marketed to midlife women (e.g., BPC-157, TB-4/TB-500, CJC-1295, ipamorelin, GHK-Cu, thymosin-α1, MOTS-C) lack robust human evidence, are not FDA-approved for human use, and have prompted FDA warning letters to compounders.

• Potential harms of unregulated peptide therapy include unpredictable immune/hormonal effects, pro-angiogenic activity with theoretical cancer risk, and contamination risks from poorly regulated compounding pharmacies.

• Creatine (oral) supports ATP regeneration and, as an adjunct to resistance training and adequate protein intake, can modestly improve muscle strength/mass; it is not a stand-alone solution.

• In postmenopausal women, creatine supplementation did not improve bone mineral density in a randomized trial, although muscle/strength gains may still occur when combined with training.

• Claims for creatine’s cognitive or mood benefits are preliminary and inconsistent; small trials/meta-analyses suggest at best modest effects (possibly greater in older or low–creatine individuals). Oral creatine monohydrate at 3–5 g/day is generally safe; use caution in kidney disease and choose third-party tested products. Do not inject creatine.

Avoid peptide injections outside legitimate clinical trials due to lack of human efficacy data and meaningful safety oversight; conversely, consider creatine monohydrate as a generally safe, adjunctive aid to resistance training in midlife women, recognizing limited evidence for bone, cognition, and mood outcomes.

When counseling perimenopausal/postmenopausal patients asking about supplements, advise against peptide injections and, for those actively doing resistance training without kidney disease, consider a trial of oral creatine monohydrate 3–5 g/day from a third-party tested brand, avoiding high doses and monitoring renal status if there is any kidney history.

URL: Listen Here

Dr. Hirsch examines whether menopausal HRT should be cycled and concludes that cycling postmenopause is usually counterproductive—inducing withdrawal bleeding, requiring synthetic progestins, and potentially provoking endothelial vasospasm and symptom recurrence—while steady dosing is safer and more tolerable. In contrast, selective cycling or use of combined oral contraceptives can be helpful during perimenopause to smooth large hormonal swings; management should be individualized via shared decision-making. The episode’s guidance is largely expert opinion grounded in clinical experience rather than direct randomized trials comparing cyclic versus continuous HRT in postmenopause.

• Postmenopausal hormone therapy (HRT) is best delivered as steady, continuous dosing; cycling postmenopause mimics reproductive physiology without conferring benefit and can worsen symptoms.

• Inducing cyclic bleeding after menopause typically requires high-dose synthetic progestins (e.g., medroxyprogesterone acetate), which many patients prefer to avoid and which can cause anxiety, expense, and local tissue dryness.

• Starting and stopping estrogen may trigger vasospasm and the return of vasomotor and genitourinary symptoms; a stable estrogen dose is physiologically safer for vascular endothelium.

• In perimenopause, targeted or cyclical use of progesterone and/or estrogen—or use of combined oral contraceptives—can help offset large hormonal fluctuations and symptom spikes.

• Shared decision-making and individualized regimens (including guided self-titration in perimenopause) are emphasized over one-size-fits-all approaches.

For postmenopausal patients, continuous estrogen (and continuous progesterone if the uterus is intact) is generally preferable to cyclic regimens because cycling adds bleeding and potential vascular instability without clear clinical advantage.

When initiating HRT in a postmenopausal patient, use a stable-dose transdermal or oral estradiol regimen and continuous micronized progesterone if the uterus is present, and avoid cyclic high-dose progestins and any start–stop estrogen patterns.

URL: Listen Here

This episode delivers a practical, evidence‑informed approach to mitigating menopause‑related collagen loss: a simplified routine built on antioxidants, retinoids, moisturizer, and rigorous sun protection, plus selective in‑office options to accelerate results. It emphasizes microneedling for robust collagen induction across skin types, delineates where IPL fits (and where it does not), and clarifies when resurfacing/tightening devices or surgery are more appropriate.

• Post‑menopausal skin is thinner, drier, more sensitive, and slower to turn over; simplify and adapt routines: gentle cleanse (or water rinse) in the AM, antioxidant serum (e.g., vitamin C), moisturizer as needed, and daily broad‑spectrum sunscreen.

• Retinoids are the cornerstone of evening care for collagen support, turnover, and dyschromia; start low/slow, consider encapsulated or OTC options (retinol, adapalene) or bakuchiol for better tolerability, and always follow with a moisturizer.

• Exfoliate sparingly (about once weekly or less) and avoid physical scrubs/mechanical brushes; if using prescription tretinoin consistently, additional exfoliation is often unnecessary.

• In‑office options that truly move the needle include red/near‑infrared light (collagen/elastin support with consistent use), IPL for mixed reds/browns in lighter skin (avoid in darker/tanned skin), and microneedling (safe for all skin types) with studies showing up to ~400% collagen increase; can be paired with PRP/growth factors.

• For more advanced photodamage or laxity, consider resurfacing lasers (CO2/Er:YAG), chemical peels, radiofrequency ± microneedling or ultrasound tightening; neurotoxins help dynamic lines (often prioritizing lower face/neck in midlife), while surgery is most appropriate when skin redundancy/laxity predominates.

For post‑menopausal patients, prioritize a barrier‑friendly, simplified regimen with nightly retinoid as tolerated and strict photoprotection; when procedural augmentation is desired, microneedling offers substantial, evidence‑based collagen induction across all skin types, while IPL should be avoided in darker or tanned skin.

Implement a menopause‑appropriate routine now: AM gentle cleanse or water rinse → antioxidant serum (preferably vitamin C in a stable, less‑irritating pump/cream) → moisturizer if needed → broad‑spectrum SPF 30+; PM gentle cleanse → low‑strength retinoid 2–3 nights/week as tolerated → moisturizer; limit exfoliation to ≤1×/week (or skip if on prescription tretinoin).

URL: Listen Here

This episode explains the ongoing U.S. estradiol patch shortage, highlighting how insurance and supply-chain intermediaries contribute to inconsistent supply and higher costs. It presents the HRT Club’s direct manufacturer-to-pharmacy, cash-based model as a practical workaround to secure steadier access and lower prices for estrogen and related hormones. Note: Some claims (e.g., timing of FDA labeling changes) reflect the speakers’ statements and were not independently verified within the episode.

• A nationwide, ongoing estradiol transdermal patch shortage is affecting multiple brands and doses; ASHP lists 14 patch products as in shortage, and ripple effects now include estradiol creams and micronized progesterone.

• Demand for estrogen patches has surged (reported 162% increase over two years), with the episode attributing part of the rise to an FDA change removing the menopausal hormone therapy black box warning in Nov 2025 and noting roughly 1 in 20 women aged 45–54 may now use estrogen prescriptions.

• Traditional supply-chain middlemen (wholesalers, PBMs) and insurance ‘guardrails’ drive high prices, dosing limits, and inconsistent brand fills, disrupting symptom control for patients.

• The HRT Club offers a direct-from-manufacturer-to-partner-pharmacy model (no insurance), aiming for steadier supply and lower cash prices (e.g., Estrogel about $30 vs retail ~$158; patches ~$48 vs ~$72; Androgel ~$40 vs ~$734; 3-tube testosterone gel pack ~$18).

• Patients can transfer prescriptions easily to the HRT Club’s partner pharmacy for home delivery; clinicians can e-prescribe directly, request 90-day supplies when appropriate, and expect LegitScript-certified operations available in all 50 states.

During the estradiol patch shortage, channeling prescriptions through direct-to-manufacturer cash pathways (e.g., HRT Club) can stabilize access, minimize insurance-related barriers, and maintain brand and dose consistency—key to preserving symptom control in menopausal hormone therapy.

If a patient cannot fill an estradiol patch, initiate an immediate prescription transfer to Transition Pharmacy Services via thehrtclub.com (or e-prescribe directly), discuss equivalent alternatives like estradiol gel, and when clinically appropriate request a 90-day supply to reduce month-to-month disruptions.

URL: Listen Here

This episode outlines lifestyle strategies to lower epithelial ovarian cancer risk—minimizing saturated animal fat, avoiding alcohol and smoking, increasing physical activity, managing weight, and abstaining from genital talc use. The host underscores that these measures reduce risk (shared largely with breast cancer risk reduction) but are not as powerful as risk-reducing surgery or combined estrogen–progestin birth control; specific effect sizes are not quantified in this episode.

• Modifiable lifestyle factors that raise epithelial ovarian cancer (EOC) risk—saturated animal fat intake, alcohol use, smoking, sedentary behavior, and obesity—largely overlap with those for breast cancer; improving these can lower risk for both.

• Replacing saturated animal fats with plant-based fats (e.g., nuts, avocados, olive oil) is emphasized as a risk-reducing dietary shift for EOC.

• Smoking cessation is particularly impactful because smoking-associated EOC risk persists for up to ~20 years after exposure.

• Regular physical activity and weight reduction (if overweight/obese) are encouraged; social environment strongly influences adherence to active, health-promoting habits.

• Avoiding genital/perineal talcum powder is a distinct behavior to reduce EOC risk via minimizing pelvic inflammation; this does not affect risk of other cancers.

Targeting shared, modifiable lifestyle risks—especially saturated animal fat intake, alcohol, smoking, inactivity, and obesity—offers practical, concurrent risk reduction for both epithelial ovarian and breast cancers, while recognizing that lifestyle changes reduce (but do not eliminate) risk and are less potent than risk-reducing surgery or combined estrogen–progestin contraceptives.

In menopause visits, implement a brief, structured EOC risk-reduction checklist that includes: counsel to eliminate genital talc use, assess and support alcohol moderation/cessation, initiate smoking-cessation planning, set concrete physical-activity goals, and create a nutrition plan to replace animal fats with plant fats and achieve weight loss if indicated.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.

👉Discover the Menopause Premium Program